title: CREB, memory enhancement and the treatment of memory disorders: promises, pitfalls and prospects.
abstract: The treatment of memory disorders, such as the gradual weakening of memory with age, the ravages of Alzheimer's disease and the cognitive deficits in various forms of mental retardation, may greatly benefit from a better understanding of the molecular and cellular mechanisms of memory formation. There is increasing interest in the possibility of pharmacologically enhancing learning and memory even in the absence of specific anatomically evident pathology. Substantial evidence in experimental systems ranging from molluscs to humans indicates that the cAMP response element binding protein (CREB) is a core component of the molecular switch that converts short- to long-term memory. Recent studies have greatly strengthened and refined our understanding of the role of CREB in learning and memory in mammals, in addition to providing greater insight into the molecular mechanisms of CREB regulation and function. This involvement of CREB and the upstream signalling pathways leading to its activation in learning-associated plasticity makes them attractive targets for drugs aimed at improving memory function, in both diseased and healthy individuals. However, CREB and its close relatives cAMP response element modulator and activating transcription factor-1 are ubiquitous proteins with several critical functions. This creates hurdles that the authors believe may limit the usefulness of CREB per se as a target for the development of memory-enhancing drugs, and focus on components of the upstream signalling pathways or on specific downstream targets will be required.
authors.affiliation: Center for Neurobiology and Behavior, College of Physicians and Surgeons of Columbia University, 1051 Riverside Drive, New York, NY 10032, USA.
authors.forename: Angel
authors.initials: A
authors.lastname: Barco
authors.forename: Christopher
authors.initials: C
authors.lastname: Pittenger
authors.forename: Eric R
authors.initials: ER
authors.lastname: Kandel
mesh_terms: D000595:Amino Acid Sequence; D000818:Animals; D030801:Animals, Genetically Modified; D017209:Apoptosis / Q000187:drug effects / Q000502:physiology; D000242:Cyclic AMP / Q000502:physiology; D017362:Cyclic AMP Response Element-Binding Protein / Q000737:chemistry / Q000502:physiology*; D015195:Drug Design; D005786:Gene Expression Regulation; D006801:Humans; D007858:Learning / Q000187:drug effects; D007859:Learning Disabilities / Q000188:drug therapy / Q000503:physiopathology; D008568:Memory / Q000502:physiology*; D008569:Memory Disorders / Q000188:drug therapy* / Q000503:physiopathology; D051379:Mice; D008954:Models, Biological; D008958:Models, Molecular; D008969:Molecular Sequence Data; D009474:Neurons / Q000166:cytology / Q000187:drug effects; D018697:Nootropic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D011487:Protein Conformation; D015290:Second Messenger Systems / Q000187:drug effects / Q000502:physiology
chemical_list: C115163:CREB1 protein, human; D017362:Cyclic AMP Response Element-Binding Protein; D018697:Nootropic Agents; D000242:Cyclic AMP